LL-37
Educational resource. Not medical advice. No dosing or instructions.
Safety grade
5/10
Moderate
Also known as
cathelicidinhcap18ll37ll 37ll-37
AA sequence
Not available yet.
What it is
LL-37 is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.
Why people are interested in this peptide and how it is commonly discussed in real-world wellness, rehabilitation, and athletic communities.
Why people are interested
- a bioactive compound discussed in research and/or clinical contexts
- this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols
- general recovery and resilience interest (anecdotal)
- common biohacker curiosity due to community reports
- interest in mechanisms suggested by early evidence
- used in goal-based stacking discussions (anecdotal)
- exploration in wellness communities despite evidence limits
LL-37 is a human antimicrobial peptide studied in immunity and inflammation. Outside of clinical research, product claims often outpace evidence and quality control is a major concern.
Common reasons people consider it
- research relevance in innate immunity and antimicrobial activity
- inflammation and skin-related discussions in some communities (evidence mixed)
- sometimes discussed in chronic infection or biofilm narratives (claims often exceed data)
Most commonly reported downsides
- injection or site irritation (when used improperly)
- headache
- fatigue
Rare but important symptoms to watch for
These are uncommon, but if they occur, stop and seek medical care.
- severe allergic reaction symptoms (hives, facial swelling, trouble breathing)
- rapidly worsening inflammatory symptoms or severe swelling
- chest pain, fainting, or severe shortness of breath
Who should be cautious
- people with autoimmune disease or immune dysregulation
- people on prescription immunosuppressants or immunomodulators
- pregnant or breastfeeding individuals
- adolescents (limited evidence and immune-development uncertainty)
Interactions summarize known or plausible ways this peptide may intersect with medications, supplements, or physiologic states. Use this as a risk-awareness map: what to ask about, what to watch for, and what deserves a clinician conversation.
Medication classes
Supplement classes
None
Other peptides
None
Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.
No curated human clinical sources have been added yet.
Status reflects how LL-37 appears in clinical literature and/or real-world contexts. This is descriptive only. Classification describes what LL-37 is and the general domain where it appears.
Pep-Talk is informational only and not medical advice. We make no warranties and are not liable for actions you take. You are responsible for your decisions and outcomes.
Community notes
Educational discussion only. No dosing, protocols, schedules, or instructions. Submissions are moderated before appearing.
Loading…
Submit a note